← All Sponsors
SPONSOR

Olema Pharmaceuticals, Inc.

Total Trials
1
Recruiting
1
Phases
Phase 3
Conditions studied: Breast CancerLocally Advanced Breast CancerMetastatic Breast CancerER Positive Breast CancerHER2 Negative Breast Carcinoma
NCT07085767 Phase 3
Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Breast Cancer
United States, Australia, Canada View Trial →